Login / Signup

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.

Kristina S BoyeJérémie LebrecAnne DibElke HeitmannMarco Orsini FedericiMaria YuHélène SapinAnnabel BarrettBruno GuerciFrancesco GiorginoMartin FüchtenbuschLuis-Emilio Garcia-Perez
Published in: Diabetes, obesity & metabolism (2023)
Improvements in PROs observed in TROPHIES, which were more evident with dulaglutide than liraglutide, reflect a relevant clinical benefit. From the patients' perspective, satisfaction, and confidence in continuing treatment with GLP-1RAs is likely to contribute to long-term treatment persistence.
Keyphrases
  • patient reported outcomes
  • type diabetes
  • newly diagnosed
  • ejection fraction
  • prognostic factors
  • cardiovascular disease
  • adipose tissue
  • combination therapy
  • weight loss